Regulation of Cellular Processes by Interleukin-16 in Homeostasis and Cancer

Journal of Cellular Physiology

Volumn 229, Issue 2, 2014, Pages 139-147

  Richmond, Jillian ^a,b   Tuzova, Marina ^a   Cruikshank, William ^a   Center, David ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 16; NEUTRALIZING ANTIBODY; SMALL INTERFERING RNA;

ARTICLE; BIOLOGICAL ACTIVITY; BREAST CANCER; CANCER GROWTH; CELL CYCLE REGULATION; CELL GROWTH; CUTANEOUS T CELL LYMPHOMA; GENE STRUCTURE; HOMEOSTASIS; HUMAN; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN STRUCTURE; TUMOR GROWTH;

GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEOSTASIS; HUMANS; INTERLEUKIN-16; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84886264838     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24441     Document Type: Article

References (91)

1. Al-Ahmadi W, Al-Ghamdi M, Al-Souhibani N, Khabar KS. 2013. miR-29a inhibition normalizes HuR over-expression and aberrant AU-rich mRNA stability in invasive cancer. J Pathol 230:28-38.
2. Alexandrakis MG, Passam FH, Kyriakou DS, Christophoridou AV, Perisinakis K, Hatzivasili A, Foudoulakis A, Castanas E. 2004. Serum level of interleukin-16 in multiple myeloma patients and its relationship to disease activity. Am J Hematol 75:101-106.
3. Allegra A, Alonci A, Bellomo G, Granata A, Tolomeo A, Penna G, Russo S, Sabattini E, Musolino C. 2010. Serum levels of interleukin-16 in a multiple myeloma patient with cutaneous involvement. Int J Dermatol 49:435-437.
4. Atanackovic D, Hildebrandt Y, Templin J, Cao Y, Keller C, Panse J, Meyer S, Reinhard H, Bartels K, Lajmi N, Sezer O, Zander AR, Marx AH, Uhlig R, Zustin J, Bokemeyer C, Kroger N. 2012. Role of interleukin 16 in multiple myeloma. J Natl Cancer Inst 104:1005-1020.
5. Azimzadeh P, Romani S, Mohebbi SR, Kazemian S, Vahedi M, Almasi S, Fatemi SR, Zali MR. 2011. Interleukin-16 (IL-16) gene polymorphisms in Iranian patients with colorectal cancer. J Gastrointestin Liver Dis 20:371-376.
6. Azimzadeh P, Romani S, Mohebbi SR, Mahmoudi T, Vahedi M, Fatemi SR, Zali N, Zali MR. 2012. Association of polymorphisms in microRNA-binding sites and colorectal cancer in an Iranian population. Cancer Genet 205:501-507.
7. Bandeira-Melo C, Sugiyama K, Woods LJ, Phoofolo M, Center DM, Cruikshank WW, Weller PF. 2002. IL-16 promotes leukotriene C(4) and IL-4 release from human eosinophils via CD4- and autocrine CCR3-chemokine-mediated signaling. J Immunol 168:4756-4763.
8. Bannert N, Adler HS, Werner A, Baier M, Kurth R. 1998. Molecular cloning and sequence analysis of interleukin 16 from nonhuman primates and from the mouse. Immunogenetics 47:390-397.
9. Bannert N, Avots A, Baier M, Serfling E, Kurth R. 1999a. GA-binding protein factors, in concert with the coactivator CREB binding protein/p300, control the induction of the interleukin 16 promoter in T lymphocytes. Proc Natl Acad Sci USA 96:1541-1546.
10. Bannert N, Kurth R, Baier M. 1999b. The gene encoding mouse interleukin-16 consists of seven exons and maps to chromosome 7: D2-D3. Immunogenetics 49:704-706.
11. Bannert N, Vollhardt K, Asomuddinov B, Haag M, Konig H, Norley S, Kurth R. 2003. PDZ domain-mediated interaction of interleukin-16 precursor proteins with myosin phosphatase targeting subunits. J Biol Chem 278:42190-42199.
12. Batai K, Shah E, Murphy AB, Newsome J, Ruden M, Ahaghotu C, Kittles RA. 2012. Fine-mapping of IL16 gene and prostate cancer risk in African Americans. Cancer Epidemiol Biomarkers Prev 21:2059-2068.
13. Cao Y, Luetkens T, Kobold S, Hildebrandt Y, Gordic M, Lajmi N, Meyer S, Bartels K, Zander AR, Bokemeyer C, Kroger N, Atanackovic D. 2010. The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients. Exp Hematol 38:860-867.
14. Center DM, Cruikshank W. 1982. Modulation of lymphocyte migration by human lymphokines. I. Identification and characterization of chemoattractant activity for lymphocytes from mitogen-stimulated mononuclear cells. J Immunol 128:2563-2568.
15. Center DM, Cruikshank WW, Berman JS, Beer DJ. 1983. Functional characteristics of histamine receptor-bearing mononuclear cells. I. Selective production of lymphocyte chemoattractant lymphokines with histamine used as a ligand. J Immunol 131:1854-1859.
16. Center DM, Kornfeld H, Cruikshank WW. 1996. Interleukin 16 and its function as a CD4 ligand. Immunol Today 17:476-481.
17. Center DM, Cruikshank WW, Zhang Y. 2004. Nuclear pro-IL-16 regulation of T cell proliferation: p27(KIP1)-dependent G0/G1 arrest mediated by inhibition of Skp2 transcription. J Immunol 172:1654-1660.
18. Chupp GL, Wright EA, Wu D, Vallen-Mashikian M, Cruikshank WW, Center DM, Kornfeld H, Berman JS. 1998. Tissue and T cell distribution of precursor and mature IL-16. J Immunol 161:3114-3119.
19. Cicala C, Arthos J, Ruiz M, Vaccarezza M, Rubbert A, Riva A, Wildt K, Cohen O, Fauci AS. 1999. Induction of phosphorylation and intracellular association of CC chemokine receptor 5 and focal adhesion kinase in primary human CD4+ T cells by macrophage-tropic HIV envelope. J Immunol 163:420-426.
20. Comperat E, Roupret M, Drouin SJ, Camparo P, Bitker MO, Houlgatte A, Cancel-Tassin G, Cussenot O. 2010. Tissue expression of IL16 in prostate cancer and its association with recurrence after radical prostatectomy. Prostate 70:1622-1627.
21. Conti P, Kempuraj D, Kandere K, Di Gioacchino M, Reale M, Barbacane RC, Castellani ML, Mortari U, Boucher W, Letourneau R, Theoharides TC. 2002. Interleukin-16 network in inflammation and allergy. Allergy Asthma Proc 23:103-108.
22. Croq F, Vizioli J, Tuzova M, Tahtouh M, Sautiere PE, Van Camp C, Salzet M, Cruikshank WW, Pestel J, Lefebvre C. 2010. A homologous form of human interleukin 16 is implicated in microglia recruitment following nervous system injury in leech Hirudo medicinalis. Glia 58:1649-1662.
23. Cruikshank W, Center DM. 1982. Modulation of lymphocyte migration by human lymphokines. IPurification of a lymphotactic factor (LCF). J Immunol 128:2569-2574.
24. Cruikshank W, Little F. 2008. lnterleukin-16: The ins and outs of regulating T-cell activation. Crit Rev Immunol 28:467-483.
25. Cruikshank WW, Berman JS, Theodore AC, Bernardo J, Center DM. 1987. Lymphokine activation of T4+ T lymphocytes and monocytes. J Immunol 138:3817-3823.
26. Cruikshank WW, Center DM, Nisar N, Wu M, Natke B, Theodore AC, Kornfeld H. 1994. Molecular and functional analysis of a lymphocyte chemoattractant factor: Association of biologic function with CD4 expression. Proc Natl Acad Sci USA 91:5109-5113.
27. Cruikshank WW, Lim K, Theodore AC, Cook J, Fine G, Weller PF, Center DM. 1996. IL-16 inhibition of CD3-dependent lymphocyte activation and proliferation. J Immunol 157:5240-5248.
28. Curiel-Lewandrowski C, Yamasaki H, Si CP, Jin X, Zhang Y, Richmond J, Tuzova M, Wilson K, Sullivan B, Jones D, Ryzhenko N, Little F, Kupper TS, Center DM, Cruikshank WW. 2011. Loss of nuclear pro-IL-16 facilitates cell cycle progression in human cutaneous T cell lymphoma. J Clin Invest 121:4838-4849.
29. Engel S, Schluesener H, Mittelbronn M, Seid K, Adjodah D, Wehner HD, Meyermann R. 2000. Dynamics of microglial activation after human traumatic brain injury are revealed by delayed expression of macrophage-related proteins MRP8 and MRP14. Acta Neuropathol 100:313-322.
30. Fenster CP, Chisnell HK, Fry CR, Fenster SD. 2010. The role of CD4-dependent signaling in interleukin-16 induced c-Fos expression and facilitation of neurite outgrowth in cerebellar granule neurons. Neurosci Lett 485:212-216.
31. Ferland C, Flamand N, Davoine F, Chakir J, Laviolette M. 2004. IL-16 activates plasminogen-plasmin system and promotes human eosinophil migration into extracellular matrix via CCR3-chemokine-mediated signaling and by modulating CD4 eosinophil expression. J Immunol 173:4417-4424.
32. Feske S, Giltnane J, Dolmetsch R, Staudt LM, Rao A. 2001. Gene regulation mediated by calcium signals in T lymphocytes. Nature Immunol 4:316-324.
33. Gao LB, Rao L, Wang YY, Liang WB, Li C, Xue H, Zhou B, Sun H, Li Y, Lv ML, Du XJ, Zhang L. 2009. The association of interleukin-16 polymorphisms with IL-16 serum levels and risk of colorectal and gastric cancer. Carcinogenesis 30:295-299.
34. Glass WG, Sarisky RT, Vecchio AM. 2006. Not-so-sweet sixteen: The role of IL-16 in infectious and immune-mediated inflammatory diseases. J Interferon Cytokine Res 26:511-520.
35. Guo LH, Mittelbronn M, Brabeck C, Mueller CA, Schluesener HJ. 2004. Expression of interleukin-16 by microglial cells in inflammatory, autoimmune, and degenerative lesions of the rat brain. J Neuroimmunol 146:39-45.
36. Jacobs TG, Yeager M, Kraft P, Wacholder S, Orr N, Yu K, Chatterjee N, Welch R, Hutchinson A, Crenshaw A, Cancel-Tassin G, Staats BJ, Wang Z, Gonzalez-Bosquet J, Fang J, Deng X, Berndt SI, Calle EE, Feigelson HS, Thun MJ, Rodriguez C, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Giovannucci E, Willett WC, Cussenot O, Valeri A, Andriole GL, Crawford ED, Tucker M, Gerhard DS, Fraumeni JF Jr., Hoover R, Hayes RB, Hunter DJ, Chanock SJ. 2008. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 40:310-315.
37. Kaser A, Dunzendorfer S, Offner FA, Ryan T, Schwabegger A, Cruikshank WW, Wiedermann CJ, Tilg H. 1999. A role for IL-16 in the cross-talk between dendritic cells and T cells. J Immunol 163:3232-3238.
38. Keane J, Nicoll J, Kim S, Wu DM, Cruikshank WW, Brazer W, Natke B, Zhang Y, Center DM, Kornfeld H. 1998. Conservation of structure and function between human and murine IL-16. J Immunol 160:5945-5954.
39. Kim HS. 1999. Assignment of human interleukin 16 (IL16) to chromosome 15q26.3 by radiation hybrid mapping. Cytogenet Cell Genet 84:93.
40. Koike M, Sekigawa I, Okada M, Matsumoto M, Iida N, Hashimoto H, Oshimi K. 2002. Relationship between CD4(+)/CD8(+) T cell ratio and T cell activation in multiple myeloma: Reference to IL-16. Leuk Res 26:705-711.
41. Kovacs E. 2001 The serum levels of IL-12 and IL-16 in cancer patients. Relation to the tumour stage and previous therapy. Biomed Pharmacother 55:111-116.
42. Kurschner C, Yuzaki M. 1999. Neuronal interleukin-16 (NIL-16): A dual function PDZ domain protein. J Neurosci 19:7770-7780.
43. Laberge S, Cruikshank WW, Beer DJ, Center DM. 1996. Secretion of IL-16 (lymphocyte chemoattractant factor) from serotonin-stimulated CD8+ T cells in vitro. J Immunol 156:310-315.
44. Lim KG, Wan HC, Bozza PT, Resnick MB, Wong DT, Cruikshank WW, Kornfeld H, Center DM, Weller PF. 1996. Human eosinophils elaborate the lymphocyte chemoattractants. IL-16 (lymphocyte chemoattractant factor) and RANTES. J Immunol 156:2566-2570.
45. Little FF, Cruikshank WW. 2004. Interleukin-16 and peptide derivatives as immunomodulatory therapy in allergic lung disease. Expert Opin Biol Ther 4:837-846.
46. Little FF, Cruikshank WW, Center DM. 2001. Il-9 stimulates release of chemotactic factors from human bronchial epithelial cells. Am J Respir Cell Mol Biol 25:347-352.
47. Liu Y, Cruikshank WW, O'Loughlin T, O'Reilly P, Center DM, Kornfeld H. 1999. Identification of a CD4 domain required for interleukin-16 binding and lymphocyte activation. J Biol Chem 274:23387-23395.
48. Liu C, Mills J, Dixon K, Vennarini J, Cunningham M, Del Vecchio A, Das A, Glass W. 2007. IL-16 signaling specifically induces STAT6 activation through CD4. Cytokine 38:145-150.
49. Lynch EA, Heijens CA, Horst NF, Center DM, Cruikshank WW. 2003. Cutting edge: IL-16/CD4 preferentially induces Th1 cell migration: Requirement of CCR5. J Immunol 171:4965-4968.
50. Mahindra A, Anderson KC. 2012. Role of interleukin 16 in multiple myeloma pathogenesis: a potential novel therapeutic target? J Natl Cancer Inst 104:964-965.
51. Marzec M, Liu X, Kasprzycka M, Witkiewicz A, Raghunath PN, El-Salem M, Robertson E, Odum N, Wasik MA. 2008. IL-2- and IL-15-induced activation of the rapamycin-sensitive mTORC1 pathway in malignant CD4+ T lymphocytes. Blood 111:2181-2189.
52. Mashikian MV, Ryan TC, Seman A, Brazer W, Center DM, Cruikshank WW. 1999. Reciprocal desensitization of CCR5 and CD4 is mediated by IL-16 and macrophage-inflammatory protein-1 beta, respectively. J Immunol 163:3123-3130.
53. Mathy NL, Bannert N, Norley SG, Kurth R. 2000. Cutting edge: CD4 is not required for the functional activity of IL-16. J Immunol 164:4429-4432.
54. McFadden C, Morgan R, Rahangdale S, Green D, Yamasaki H, Center D, Cruikshank W. 2007. Preferential migration of T regulatory cells induced by IL-16. J Immunol 179:6439-6445.
55. Meagher C, Beilke J, Arreaza G, Mi QS, Chen W, Salojin K, Horst N, Cruikshank WW, Delovitch TL. 2010. Neutralization of interleukin-16 protects nonobese diabetic mice from autoimmune type 1 diabetes by a CCL4-dependent mechanism. Diabetes 59:2862-2871.
56. Milke L, Schulz K, Weigert A, Sha W, Schmid T, Brüne B. 2013. Depletion of tristetraprolin in breast cancer cells increases interleukin-16 expression and promotes tumor infiltration with monocytes/macrophages. Carcinogenesis 34:850-857.
57. Min W, Lillehoj HS. 2004. Identification and characterization of chicken interleukin-16 cDNA. Dev Comp Immunol 28:153-162.
58. Muhlhahn P, Zweckstetter M, Georgescu J, Ciosto C, Renner C, Lanzendorfer M, Lang K, Ambrosius D, Baier M, Kurth R, Holak TA. 1998. Structure of interleukin 16 resembles a PDZ domain with an occluded peptide binding site. Nat Struct Biol 5:682-686.
59. Nicoll J, Cruikshank WW, Brazer W, Liu Y, Center DM, Kornfeld H. 1999. Identification of domains in IL-16 critical for biological activity. J Immunol 163:1827-1832.
60. Ogasawara H, Takeda-Hirokawa N, Sekigawa I, Hashimoto H, Kaneko Y, Hirose S. 1999. Inhibitory effect of interleukin-16 on interleukin-2 production by CD4+ T cells. Immunology 96:215-219.
61. Parada NA, Cruikshank WW, Danis HL, Ryan TC, Center DM. 1996. IL-16- and other CD4 ligand-induced migration is dependent upon protein kinase C. Cell Immunol 168:100-106.
62. Parada NA, Center DM, Kornfeld H, Rodriguez WL, Cook J, Vallen M, Cruikshank WW. 1998. Synergistic activation of CD4+ T cells by IL-16 and IL-2. J Immunol 160:2115-2120.
63. Pritchard J, Horst N, Cruikshank W, Smith TJ. 2002. Igs from patients with Graves' disease induce the expression of T cell chemoattractants in their fibroblasts. J Immunol 168:942-950.
64. Qi JC, Wang J, Mandadi S, Tanaka K, Roufogalis BD, Madigan MC, Lai K, Yan F, Chong BH, Stevens RL, Krilis SA. 2006. Human and mouse mast cells use the tetraspanin CD9 as an alternate interleukin-16 receptor. Blood 107:135-142.
65. Qin XJ, Shi HZ, Huang ZX, Kang LF, Mo WN, Wu C. 2005. Interleukin-16 in tuberculosis and malignant pleural effusions. Eur Respir J 25:605-611.
66. Rahangdale S, Morgan R, Heijens C, Ryan TC, Yamasaki H, Bentley E, Sullivan E, Center DM, Cruikshank WW. 2006. Chemokine receptor CXCR3 desensitization by IL-16/CD4 signaling is dependent on CCR5 and intact membrane cholesterol. J Immunol 176:2337-2345.
67. Rand TH, Cruikshank WW, Center DM, Weller PF. 1991a. CD4-mediated stimulation of human eosinophils: Lymphocyte chemoattractant factor and other CD4-binding ligands elicit eosinophil migration. J Exp Med 173:1521-1528.
68. Rand TH, Silberstein DS, Kornfeld H, Weller PF. 1991b. Human eosinophils express functional interleukin 2 receptors. J Clin Invest 88:825-832.
69. Reich K, Heine A, Hugo S, Blaschke V, Middel P, Kaser A, Tilg H, Blaschke S, Gutgesell C, Neumann C. 2001. Engagement of the Fc epsilon RI stimulates the production of IL-16 in Langerhans cell-like dendritic cells. J Immunol 167:6321-6329.
70. Ren F, Zhan X, Martens G, Lee J, Center D, Hanson SK, Kornfeld H. 2005. Pro-IL-16 regulation in activated murine CD4+ lymphocytes. J Immunol 174:2738-2745.
71. Richmond J, Tuzova M, Parks A, Adams N, Martin E, Tawa M, Morrison L, Chaney K, Kupper TS, Curiel-Lewandrowski C, Cruikshank W. 2011. Interleukin-16 as a marker of Sezary syndrome onset and stage. J Clin Immunol 31:39-50.
72. Rumsaeng V, Cruikshank WW, Foster B, Prussin C, Kirshenbaum AS, Davis TA, Kornfeld H, Center DM, Metcalfe DD. 1997. Human mast cells produce the CD4+ T lymphocyte chemoattractant factor, IL-16. J Immunol 159:2904-2910.
73. Ryan TC, Cruikshank WW, Kornfeld H, Collins TL, Center DM. 1995. The CD4-associated tyrosine kinase p56lck is required for lymphocyte chemoattractant factor-induced T lymphocyte migration. J Biol Chem 270:17081-17086.
74. Schwab JM, Nguyen TD, Meyermann R, Schluesener HJ. 2001. Human focal cerebral infarctions induce differential lesional interleukin-16 (IL-16) expression confined to infiltrating granulocytes, CD8+ T-lymphocytes and activated microglia/macrophages. J Neuroimmunol 114:232-241.
75. Sciaky D, Brazer W, Center DM, Cruikshank WW, Smith TJ. 2000. Cultured human fibroblasts express constitutive IL-16 mRNA: Cytokine induction of active IL-16 protein synthesis through a caspase-3-dependent mechanism. J Immunol 164:3806-3814.
76. Seegert D, Schreiber S. 2002. Overview: Interleukin-16 and its role in inflammatory bowel disease. Curr Opin Invest Drug 3:562-564.
77. Stoitzner P, Ratzinger G, Koch F, Janke K, Scholler T, Kaser A, Tilg H, Cruikshank WW, Fritsch P, Romani N. 2001. Interleukin-16 supports the migration of Langerhans cells, partly in a CD4-independent way. J Invest Dermatol 116:641-649.
78. Szabo P, Zhao K, Kirman I, Le Maoult J, Dyall R, Cruikshank W, Weksler ME. 1998. Maturation of B cell precursors is impaired in thymic-deprived nude and old mice. J Immunol 161:2248-2253.
79. Tamma SM, Chirmule N, McCloskey TW, Oyaizu N, Kalyanaraman VS, Pahwa S. 1997. Signals transduced through the CD4 molecule interfere with TCR/CD3-mediated ras activation leading to T cell anergy/apoptosis. Clin Immunol Immunopathol 85:195-201.
80. Theodore AC, Center DM, Nicoll J, Fine G, Kornfeld H, Cruikshank WW. 1996. CD4 ligand IL-16 inhibits the mixed lymphocyte reaction. J Immunol 157:1958-1964.
81. Van Drenth C, Jenkins A, Ledwich L, Ryan TC, Mashikian MV, Brazer W, Center DM, Cruikshank WW. 2000. Desensitization of CXC chemokine receptor 4, mediated by IL-16/CD4, is independent of p56lck enzymatic activity. J Immunol 165:6356-6363.
82. Wilson KC, Cruikshank WW, Center DM, Zhang Y. 2002. Prointerleukin-16 contains a functional CcN motif that regulates nuclear localization. Biochemistry 41:14306-14312.
83. Wilson KC, Center DM, Cruikshank WW. 2004. The effect of interleukin-16 and its precursor on T lymphocyte activation and growth. Growth Factors 22:97-104.
84. Wilson KC, Cattel DJ, Wan Z, Rahangdale S, Ren F, Kornfeld H, Sullivan BA, Cruikshank WW, Center DM. 2005. Regulation of nuclear Prointerleukin-16 and p27(Kip1) in primary human T lymphocytes. Cell Immunol 237:17-27.
85. Wu DM, Zhang Y, Parada NA, Kornfeld H, Nicoll J, Center DM, Cruikshank WW. 1999. Processing and release of IL-16 from CD4+ but not CD8+ T cells is activation dependent. J Immunol 162:1287-1293.
86. Yellapa A, Bahr JM, Bitterman P, Abramowicz JS, Edassery SL, Penumatsa K, Basu S, Rotmensch J, Barua A. 2012. Association of interleukin 16 with the development of ovarian tumor and tumor-associated neoangiogenesis in laying hen model of spontaneous ovarian cancer. Int J Gynecol Cancer 22:199-207.
87. Zhang XM, Xu YH. 2002. The associated regulators and signal pathway in rIL-16/CD4 mediated growth regulation in Jurkat cells. Cell Res 12:363-372.
88. Zhang Y, Center DM, Wu DM, Cruikshank WW, Yuan J, Andrews DW, Kornfeld H. 1998. Processing and activation of pro-interleukin-16 by caspase-3. J Biol Chem 273:1144-1149.
89. Zhang Y, Kornfeld H, Cruikshank WW, Kim S, Reardon CC, Center DM. 2001. Nuclear translocation of the N-terminal prodomain of interleukin-16. J Biol Chem 276:1299-1303.
90. Zhang Y, Tuzova M, Xiao ZX, Cruikshank WW, Center DM. 2008. Pro-IL-16 recruits histone deacetylase 3 to the Skp2 core promoter through interaction with transcription factor GABP. J Immunol 180:402-408.
91. Zhu J, Qin C, Yan F, Wang M, Ding Q, Zhang Z, Yin C. 2010. IL-16 polymorphism and risk of renal cell carcinoma: Association in a Chinese population. Int J Urol 17:700-707.